Zai Lab Limited (ZLAB)
(Real Time Quote from BATS)
$20.96 USD
-0.89 (-4.07%)
Updated Sep 23, 2024 12:56 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZLAB 20.96 -0.89(-4.07%)
Will ZLAB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ZLAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZLAB
Best Momentum Stocks to Buy for July 10th
New Strong Buy Stocks for July 10th
ZLAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?
Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals
Other News for ZLAB
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
Zai Lab announced data from Phase 1 study of ZL-1218
Zai Lab Announces Participation in September Investor Conferences
Zai Lab’s Solid Market Performance and Growth Prospects Justify Buy Rating